G M Halliday

Neuroscience Research Australia, Sydney, New South Wales, Australia

Are you G M Halliday?

Claim your profile

Publications (227)992.89 Total impact

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Imaging, cerebrospinal fluid (CSF) and blood-based biomarkers have the potential to improve the accuracy by which specific causes of dementia can be diagnosed in vivo, provide insights into the underlying pathophysiology, and may be used as inclusion criteria and outcome measures for clinical trials. While a number of imaging and CSF biomarkers are currently used for each of these purposes, this is an evolving field, with numerous potential biomarkers in varying stages of research and development. We review the currently available biomarkers for the three most common forms of neurodegenerative dementia, and give an overview of research techniques that may in due course make their way into the clinic.
    Preview · Article · Sep 2014 · Journal of Neurology Neurosurgery & Psychiatry
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background The homeostatic control of emotions and metabolism is disturbed in Huntington disease (HD). We have recently shown that specific neuropeptide populations in the hypothalamus are affected in HD patients. Transcriptional dysregulation is well known to occur in HD and it has been reported also in the hypothalamus of transgenic HD mice. Less is known about the extent of transcriptional dysregulation in the different hypothalamic nuclei in clinical HD. Aim To investigate whether there are changes in gene expression levels of emotion and metabolism regulating factors in key hypothalamic circuitries in human post mortem tissues from individuals affected with HD. Methods/techniques We have dissected frozen tissue from the paraventricular nucleus, the ventromedial nucleus, the lateral hypothalamus and the supraoptic nucleus of the hypothalamus from 4 HD cases and 4 sex-and age-matched controls. The tissue was then processed for quantitative real time PCR. Results/outcome The RNA integrity value was found to be above 7 for all samples. Our results show reduced mRNA expression levels of orexin (hypocretin) in the lateral hypothalamus as well as of dopamine receptor D2 expression in HD. We have also detected reduced expression of brain-derived neurotrophic factor (BDNF) in the ventromedial hypothalamus in HD. Conclusions These results show significant and specific alterations in gene expression in key hypothalamic nuclei involved in the regulation of emotions and metabolism. Transcriptional alterations in this region may be important for the development of the early non-motor symptoms and signs in HD, and may provide potential targets for therapeutic interventions.
    No preview · Article · Sep 2014 · Journal of Neurology Neurosurgery & Psychiatry
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: α-Synuclein (SNCA) and microtubule-associated protein tau (MAPT) are the two major genes independently, but not jointly, associated with susceptibility for Parkinson's disease (PD). The SNCA gene has recently been identified as a major modifier of age of PD onset. Whether MAPT gene synergistically influences age of onset of PD is unknown. Objective. To investigate independent and joint effects of MAPT and SNCA on PD onset age. Methods: 412 patients with PD were recruited from the Australian PD Research Network (123) and the Neurology Department, Ruijin Hospital Affiliated to Shanghai Jiaotong University, China (289). MAPT (rs17650901) tagging H1/H2 haplotype and SNCA (Rep1) were genotyped in the Australian cohort, and MAPT (rs242557, rs3744456) and SNCA (rs11931074, rs894278) were genotyped in the Chinese cohort. SPSS regression analysis was used to test genetic effects on age at onset of PD in each cohort. Results: SNCA polymorphisms associated with the onset age of PD in both populations. MAPT polymorphisms did not enhance such association in either entire cohort. Conclusion: This study suggests that, in both ethnic groups, SNCA gene variants influence the age at onset of PD and α-synuclein plays a key role in the disease course of PD.
    Full-text · Article · Aug 2014 · BioMed Research International
  • Glenda Halliday
    [Show abstract] [Hide abstract]
    ABSTRACT: Definitive biomarkers for both differentiating neurodegenerative diseases and monitoring their progression over time are sorely needed. This has become particularly crucial for the development of therapies targeting core disease mechanisms.2 β-Amyloid (Aβ) and associated biomarkers have revolutionised current thoughts and theories on Alzheimer's disease (AD) with the hope that significant advances in clinical therapies can now be achieved.2 The most significant change is their use to detect asymptomatic disease due to many disappointing clinical trials in definitively diagnosed symptomatic patients.3 This change in thinking has only been possible in AD due to advances in imaging and peripheral biomarker research and their application in diverse population settings.4 To date the identification of definitive biomarkers for other neurodegenerative … [Full text of this article]
    No preview · Article · Jul 2014 · Journal of Neurology Neurosurgery & Psychiatry
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND: Frontotemporal dementia (FTD) is a complex disorder characterised by a broad range of clinical manifestations, differential pathological signatures, and genetic variability. Mutations in three genes-MAPT, GRN, and C9orf72-have been associated with FTD. We sought to identify novel genetic risk loci associated with the disorder. METHODS: We did a two-stage genome-wide association study on clinical FTD, analysing samples from 3526 patients with FTD and 9402 healthy controls. To reduce genetic heterogeneity, all participants were of European ancestry. In the discovery phase (samples from 2154 patients with FTD and 4308 controls), we did separate association analyses for each FTD subtype (behavioural variant FTD, semantic dementia, progressive non-fluent aphasia, and FTD overlapping with motor neuron disease [FTD-MND]), followed by a meta-analysis of the entire dataset. We carried forward replication of the novel suggestive loci in an independent sample series (samples from 1372 patients and 5094 controls) and then did joint phase and brain expression and methylation quantitative trait loci analyses for the associated (p<5 × 10(-8)) single-nucleotide polymorphisms. FINDINGS: We identified novel associations exceeding the genome-wide significance threshold (p<5 × 10(-8)). Combined (joint) analyses of discovery and replication phases showed genome-wide significant association at 6p21.3, HLA locus (immune system), for rs9268877 (p=1·05 × 10(-8); odds ratio=1·204 [95% CI 1·11-1·30]), rs9268856 (p=5·51 × 10(-9); 0·809 [0·76-0·86]) and rs1980493 (p value=1·57 × 10(-8), 0·775 [0·69-0·86]) in the entire cohort. We also identified a potential novel locus at 11q14, encompassing RAB38/CTSC (the transcripts of which are related to lysosomal biology), for the behavioural FTD subtype for which joint analyses showed suggestive association for rs302668 (p=2·44 × 10(-7); 0·814 [0·71-0·92]). Analysis of expression and methylation quantitative trait loci data suggested that these loci might affect expression and methylation in cis. INTERPRETATION: Our findings suggest that immune system processes (link to 6p21.3) and possibly lysosomal and autophagy pathways (link to 11q14) are potentially involved in FTD. Our findings need to be replicated to better define the association of the newly identified loci with disease and to shed light on the pathomechanisms contributing to FTD
    Full-text · Article · Jul 2014 · The Lancet Neurology

  • No preview · Conference Paper · May 2014
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Hexanucleotide repeat expansions in chromosome 9 open reading frame 72 (C9orf72) have recently been linked to frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis, and may be the most common genetic cause of both neurodegenerative diseases. Genetic variants at TMEM106B influence risk for the most common neuropathological subtype of FTLD, characterized by inclusions of TAR DNA-binding protein of 43 kDa (FTLD-TDP). Previous reports have shown that TMEM106B is a genetic modifier of FTLD-TDP caused by progranulin (GRN) mutations, with the major (risk) allele of rs1990622 associating with earlier age at onset of disease. Here, we report that rs1990622 genotype affects age at death in a single-site discovery cohort of FTLD patients with C9orf72 expansions (n = 14), with the major allele correlated with later age at death (p = 0.024). We replicate this modifier effect in a 30-site international neuropathological cohort of FTLD-TDP patients with C9orf72 expansions (n = 75), again finding that the major allele associates with later age at death (p = 0.016), as well as later age at onset (p = 0.019). In contrast, TMEM106B genotype does not affect age at onset or death in 241 FTLD-TDP cases negative for GRN mutations or C9orf72 expansions. Thus, TMEM106B is a genetic modifier of FTLD with C9orf72 expansions. Intriguingly, the genotype that confers increased risk for developing FTLD-TDP (major, or T, allele of rs1990622) is associated with later age at onset and death in C9orf72 expansion carriers, providing an example of sign epistasis in human neurodegenerative disease.
    Full-text · Article · Jan 2014 · Acta Neuropathologica
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: Clinical heterogeneity in the development of levodopa-induced dyskinesias (LID) suggests endogenous factors play a significant role in determining their overall prevalence. Objective: We hypothesised that single nucleotide polymorphisms (SNPs) in specific genes may result in a clinical phenotype conducive to an increased risk of LID. Methods: We examined the influence of SNPs in the catechol-O-methyltransferase (COMT), monoamine oxidase A (MAO-A) and brain-derived neurotrophic factor (BDNF) genes on LID in a cohort of 285 pathologically confirmed Parkinson's disease patients, using data from their complete disease course. Results: Dyskinetic patients demonstrated younger age at disease onset (60.3 vs. 66.4 years, p < 0.0001), a longer disease duration (17.0 vs. 12.0 years, p < 0.0001) and a higher maximum daily levodopa equivalent dose (LED; 926.7 vs. 617.1 mg/day, p < 0.0001) than patients without dyskinesias. No individual SNP was found to influence prevalence or time to onset of dyskinesias, including after adjustment for known risk factors. We observed that patients carrying alleles conferring both high COMT activity and increased MAO-A mRNA expression received significantly higher maximum and mean daily LEDs than those with low enzyme activity/mRNA expression (max LED: 835 ± 445 vs. 508 ± 316 mg; p = 0.0056, mean LED: 601 ± 335 vs. 398 ± 260 mg; p = 0.025). Conclusions: Individual SNPs in BDNF, COMT and MAO-A genes did not influence prevalence or time to onset of dyskinesias in this cohort. The possibility that combined COMT and MAO-A genotype is a significant factor in determining an individual's lifetime levodopa exposure warrants further investigation.
    No preview · Article · Sep 2013 · Neurodegenerative Diseases
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Both fresh-frozen and formalin-fixed, paraffinembedded (FFPE) human brain tissues are invaluable resources for molecular genetic studies of central nervous system diseases, especially neurodegenerative disorders. To identify the optimal method for DNA extraction from human brain tissue, we compared methods on differently-processed tissues. Fragments of LRRK2 and MAPT (257 bp and 483 bp/245 bp) were amplified for evaluation. We found that for FFPE samples, the success rate of DNA extraction was greater when using a commercial kit than a laboratory-based method (successful DNA extraction from 76% versus 33% of samples). PCR amplicon size and storage period were key factors influencing the success rate of DNA extraction from FFPE samples. In the fresh-frozen samples, the DNA extraction success rate was 100% using either a commercial kit (QIAamp DNA Micro) or a laboratorybased method (sample boiling in 0.1 mol/L NaOH, followed by proteinase K digestion, and then DNA extraction using Chelex-100) regardless of PCR amplicon length or tissue storage time. Although the present results demonstrate that PCR-amplifiable genomic DNA can be extracted from both fresh-frozen and FFPE samples, fresh brain tissue is recommended for DNA extraction in future neuropathological studies.
    Full-text · Article · Aug 2013 · Neuroscience Bulletin
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background and aims: Tenuigenin (Ten) is a Chinese herbal extract with antioxidative and antiinflammatory effects on toxin-induced cell models of Parkinson's disease (PD); however, its effects on α-synuclein toxicity-based PD models remain unknown. α-synuclein hyperphosphorylation is a key event in PD pathogenesis and potential target of therapeutic interventions. We tested whether Ten alleviates α-synuclein-induced cytotoxicity via reducing kinases that phosphorylate α-synuclein. Methods: SH-SY5Y cells transiently transfected with wild-type or A53T mutant α-synuclein were used to evaluate the effect of Ten on the levels of α-synuclein phosphorylation-related kinases. Cells treated with 10 μM Ten for 24 h were measured for viability (proliferation and apoptosis assays) and cellular proteins harvested and fractioned. The levels of total and phosphorylated α-synuclein and five associated kinases (polo-like kinase [PLK] 1-3, casein kinase [CK] 1-2) were evaluated by Western blotting. Results: Overexpression of either wild-type or A53T mutant α-synuclein decreased cell viability and increased α-synuclein phosphorylation. Ten treatment-protected cells from this α-synuclein-induced toxicity and dramatically reduced α-synuclein phosphorylation and PLK3 (but not other kinase) levels. Conclusion: In α-synuclein cell model of PD, Ten is effective in attenuating α-synuclein-induced toxicity and α-synuclein phosphorylation probably via targeting PLK3, suggesting it could be an efficient therapeutic drug to treat α-synuclein-related neurodegeneration.
    Full-text · Article · May 2013 · CNS Neuroscience & Therapeutics
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: IMPORTANCE While mutations in glucocerebrosidase (GBA1) are associated with an increased risk for Parkinson disease (PD), it is important to establish whether such mutations are also a common risk factor for other Lewy body disorders. OBJECTIVE To establish whether GBA1 mutations are a risk factor for dementia with Lewy bodies (DLB). DESIGN We compared genotype data on patients and controls from 11 centers. Data concerning demographics, age at onset, disease duration, and clinical and pathological features were collected when available. We conducted pooled analyses using logistic regression to investigate GBA1 mutation carrier status as predicting DLB or PD with dementia status, using common control subjects as a reference group. Random-effects meta-analyses were conducted to account for additional heterogeneity. SETTING Eleven centers from sites around the world performing genotyping. PARTICIPANTS Seven hundred twenty-one cases met diagnostic criteria for DLB and 151 had PD with dementia. We compared these cases with 1962 controls from the same centers matched for age, sex, and ethnicity. MAIN OUTCOME MEASURES Frequency of GBA1 mutations in cases and controls. RESULTS We found a significant association between GBA1 mutation carrier status and DLB, with an odds ratio of 8.28 (95% CI, 4.78-14.88). The odds ratio for PD with dementia was 6.48 (95% CI, 2.53-15.37). The mean age at diagnosis of DLB was earlier in GBA1 mutation carriers than in noncarriers (63.5 vs 68.9 years; P < .001), with higher disease severity scores. CONCLUSIONS AND RELEVANCE Mutations in GBA1 are a significant risk factor for DLB. GBA1 mutations likely play an even larger role in the genetic etiology of DLB than in PD, providing insight into the role of glucocerebrosidase in Lewy body disease.
    Full-text · Article · Apr 2013
  • Glenda Halliday · Stefanie Reyes · Kay Double

    No preview · Article · Dec 2012
  • Glenda Halliday

    No preview · Article · Nov 2012 · Movement Disorders
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Disturbances in brain copper result in rare and severe neurological disorders and may play a role in the pathogenesis and progression of multiple neurodegenerative diseases. Our current understanding of mammalian brain copper transport is based on model systems outside the central nervous system and no data are available regarding copper transport systems in the human brain. To address this deficit, we quantified regional copper concentrations and examined the distribution and cellular localization of the copper transport proteins Copper transporter 1, Atox1, ATP7A, and ATP7B in multiple regions of the human brain using inductively coupled plasma-mass spectrometry, Western blot and immunohistochemistry. We identified significant relationships between copper transporter levels and brain copper concentrations, supporting a role for these proteins in copper transport in the human brain. Interestingly, the substantia nigra contained twice as much copper than that in other brain regions, suggesting an important role for copper in this brain region. Furthermore, ATP7A levels were significantly greater in the cerebellum, compared with other brain regions, supporting an important role for ATP7A in cerebellar neuronal health. This study provides novel data regarding copper regulation in the human brain, critical to understand the mechanisms by which brain copper levels can be altered, leading to neurological disease.
    Full-text · Article · Oct 2012 · Metallomics

  • No preview · Article · Sep 2012 · Wound Repair and Regeneration

  • No preview · Article · Sep 2012 · Wound Repair and Regeneration
  • D. L. Damian · D. Surjana · A. J. Martin · G. M. Halliday

    No preview · Article · Sep 2012 · Wound Repair and Regeneration
  • N. C. Delic · P. W. Sou · G. M. Halliday · J. Lyons

    No preview · Article · Sep 2012 · Wound Repair and Regeneration
  • S.M. Thanos · G.M. Halliday · D.L. Damian
    [Show abstract] [Hide abstract]
    ABSTRACT: The immune suppressive effects of topical photodynamic therapy (PDT) are potential contributors to treatment failure after PDT for nonmelanoma skin cancer. Nicotinamide (vitamin B(3) ) prevents immune suppression by ultraviolet radiation, but its effects on PDT-induced immunosuppression are unknown. To determine the effects of topical and oral nicotinamide on PDT-induced immunosuppression in humans. Twenty healthy Mantoux-positive volunteers received 5% nicotinamide lotion or vehicle to either side of the back daily for 3 days. Another group of 30 volunteers received 500 mg oral nicotinamide or placebo twice daily for 1 week in a randomized, double-blinded, crossover design. In each study, methylaminolaevulinate cream was applied to discrete areas on the back, followed by narrowband red light irradiation (37 J cm(-2) ) delivered at high (75 mW cm(-2) ) or low (15 mW cm(-2) ) irradiance rates. Adjacent, nonirradiated sites served as controls. Delayed-type hypersensitivity (Mantoux) reactions were assessed at treatment and control sites to determine immunosuppression. High irradiance rate PDT with vehicle or with placebo caused significant immunosuppression (equivalent to 48% and 50% immunosuppression, respectively; both P < 0·0001); topical and oral nicotinamide reduced this immunosuppression by 59% and 66%, respectively (both P < 0·0001). Low irradiance rate PDT was not significantly immunosuppressive in the topical nicotinamide study (15% immunosuppression, not significant), but caused 22% immunosuppression in the oral study (placebo arm; P = 0·006); nicotinamide reduced this immunosuppression by 69% (P = 0·045). While the clinical relevance of these findings is currently unknown, nicotinamide may provide an inexpensive means of preventing PDT-induced immune suppression and enhancing PDT cure rates.
    No preview · Article · Jun 2012 · British Journal of Dermatology

  • No preview · Conference Paper · Nov 2011

Publication Stats

9k Citations
992.89 Total Impact Points

Institutions

  • 2012-2014
    • Neuroscience Research Australia
      Sydney, New South Wales, Australia
  • 1984-2014
    • University of New South Wales
      • • Faculty of Medicine
      • • School of Medical Sciences
      • • Prince of Wales Medical Research Institute
      • • Department of Anatomy
      Kensington, New South Wales, Australia
  • 1991-2012
    • Royal Prince Alfred Hospital
      • Sydney Cancer Center
      Camperdown, New South Wales, Australia
    • University of Lausanne
      Lausanne, Vaud, Switzerland
  • 1990-2012
    • University of Sydney
      • • Discipline in Dermatology
      • • Central Clinical School
      • • School of Psychology
      • • School of Biological Sciences
      Sydney, New South Wales, Australia
  • 1995-2008
    • Prince of Wales Hospital and Community Health Services
      Sydney, New South Wales, Australia
  • 2005
    • University of Cambridge
      Cambridge, England, United Kingdom
  • 2003
    • Royal North Shore Hospital
      Sydney, New South Wales, Australia
  • 1997
    • Westmead Hospital
      • Department of Neurology
      Sydney, New South Wales, Australia
  • 1992
    • The Royal Children's Hospital
      Melbourne, Victoria, Australia
  • 1985-1991
    • University of Tasmania
      • School of Medicine
      Hobart Town, Tasmania, Australia